Healthcare
This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term-care facilities, and medical equipment and supplies.
Featured
Latest Company Reports
- DEMANTDemant AS
Demant Building Momentum Toward Market Share Gains in 2026
- Rating
- Price
- DKK 289.00
- Fair Value
- >BT
- Uncertainty
- LOCK|$rr#x
- Economic Moat
- LOCK|C%xsP
- Capital Allocation
- LOCK|dp%?WX
- MMEDMinimed Group Inc
MiniMed Poised to Roll Out New Innovations in Diabetes Devices but Has Yet to Dig a Moat
- Rating
- Price
- $19.78
- Fair Value
- s?
- Uncertainty
- LOCK|Wn
- Economic Moat
- LOCK|D%
- Capital Allocation
- LOCK|q$>CJ!
- CAHCardinal Health Inc
Cardinal Wraps Up Fiscal 2026 With Revenue Softness but Margin Expansion and Earnings Growth Impress
- Rating
- Price
- $240.15
- Fair Value
- LOCK|<#
- Uncertainty
- LOCK|JW>t
- Economic Moat
- LOCK|TzNv<
- Capital Allocation
- LOCK|fnBgs!
- ALCAlcon Inc
New Launches and Pipeline Investments Support Alcon's Market Leadership and Strong Fundamentals
- Rating
- Price
- CHF 61.06
- Fair Value
- KQ>
- Uncertainty
- LOCK|Jmj&D
- Economic Moat
- LOCK|>v<PN
- Capital Allocation
- LOCK|p#DGS>#
- SOLVSolventum Corp
Solventum Doubles Down on Medtech and Plans to Separate Healthcare Information Systems
- Rating
- Price
- $84.10
- Fair Value
- psM
- Uncertainty
- LOCK|fksbB
- Economic Moat
- LOCK|gc
- Capital Allocation
- LOCK|d&d<yY
- LIVNLivaNova PLC
LivaNova Plans for Early 2027 Launch of Aura6000 for Obstructive Sleep Apnea
- Rating
- Price
- $78.63
- Fair Value
- T&f
- Uncertainty
- LOCK|l!
- Economic Moat
- LOCK|gqxn
- Capital Allocation
- LOCK|P>
- AFXCarl Zeiss Meditec AG
Zeiss Challenged by Market Developments in 2026, but Strong Long-Term Fundamentals Intact
- Rating
- Price
- €31.08
- Fair Value
- ThZ
- Uncertainty
- LOCK|v$ %<My
- Economic Moat
- LOCK|^?^?P
- Capital Allocation
- LOCK|GP^lPW
- SN.Smith & Nephew PLC
Smith & Nephew Is Under Pressure from External Factors and Portfolio Gaps
- Rating
- Price
- GBX1,108.00
- Fair Value
- LOCK|^j
- Uncertainty
- LOCK|Z^Tj
- Economic Moat
- LOCK|CSMWm
- Capital Allocation
- LOCK|@&%Hw@W
- XRAYDentsply Sirona Inc
Dentsply's Full Recovery Timeline Looks Uncertain as Tough Market and Competition Put Pressure
- Rating
- Price
- $11.61
- Fair Value
- wW@
- Uncertainty
- LOCK|#p %q^%
- Economic Moat
- LOCK|#d@
- Capital Allocation
- LOCK|>x#$P$p
- STESteris PLC
Narrow-Moat Steris' Recurring Revenue and Margin Improvement Create Opportunistic Outlook
- Rating
- Price
- $238.23
- Fair Value
- LOCK|M^
- Uncertainty
- LOCK|J&bV^
- Economic Moat
- LOCK|L>Zl
- Capital Allocation
- LOCK|z@fY@gC
- RMDResMed Inc
Resmed's Growth Rests on the Undiagnosed Majority
- Rating
- Price
- $224.84
- Fair Value
- %@f
- Uncertainty
- LOCK|s^sPl
- Economic Moat
- LOCK|&^TSW
- Capital Allocation
- LOCK|Hwf?$KN
- CRLCharles River Laboratories International Inc
Charles River Benefits From an Improving Demand Environment Despite No Moat
- Rating
- Price
- $282.00
- Fair Value
- wn@
- Uncertainty
- LOCK|jhH
- Economic Moat
- LOCK|p?@
- Capital Allocation
- LOCK|&x#^D@V
- ZTSZoetis Inc Class A
As Competition Crowds Zoetis, We Lower Our Fair Value Estimate
- Rating
- Price
- $75.35
- Fair Value
- #@Q
- Uncertainty
- LOCK|@q
- Economic Moat
- LOCK|Fh<
- Capital Allocation
- LOCK|R@jvH$D
- VTRSViatris Inc
Viatris Looks to New Launches, Pipeline Progression, and Cost Savings for Long-Term Growth
- Rating
- Price
- $16.28
- Fair Value
- d@
- Uncertainty
- LOCK|p% R<mg
- Economic Moat
- LOCK|<$
- Capital Allocation
- LOCK|V$SMGQ&
- MRKMerck KGaA
Merck's Rare-Disease Momentum to Counteract Sales Declines in Mature Healthcare Drug Portfolio
- Rating
- Price
- €140.00
- Fair Value
- LOCK|SM
- Uncertainty
- LOCK|hzGZ
- Economic Moat
- LOCK|?Z<gh
- Capital Allocation
- LOCK|^G?>V%%
Largest Stocks in the Healthcare Sector
|
1-Day Chart
|
Name
|
Industry
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Drug Manufacturers - General | LOCK|c$<#&$x | LOCK|xy | $1T | |||
| Johnson & Johnson
JNJ
| Drug Manufacturers - General | LOCK|CX>c^< | LOCK|Ml^ | $626B | |||
| AbbVie Inc
ABBV
| Drug Manufacturers - General | LOCK|yZ?>B# | LOCK|vG | $442B | |||
| UnitedHealth Group Inc
UNH
| Healthcare Plans | LOCK|q<TcWQn | LOCK|P^&XK | $361B | |||
| Merck & Co Inc
MRK
| Drug Manufacturers - General | LOCK|$FCJ!% | LOCK|y@^ | $322B | |||
| Novartis AG ADR
NVS
| Drug Manufacturers - General | LOCK|^j@zv%# | LOCK|#Y | $295B | |||
| AstraZeneca PLC
AZN
| Drug Manufacturers - General | LOCK|p$#&DGC! | LOCK|<# | $248B | |||
| Amgen Inc
AMGN
| Drug Manufacturers - General | LOCK|?by^^># | LOCK|J? | $224B | |||
| Thermo Fisher Scientific Inc
TMO
| Diagnostics & Research | LOCK|$?cXc%m$ | LOCK|@t | $224B | |||
| Novo Nordisk AS ADR
NVO
| Drug Manufacturers - General | LOCK|py&S#Q | LOCK|Xx | $210B |
More in Healthcare
AstraZeneca and Bristol-Myers Squibb: Megamerger Reports Leave Us Scratching Our Heads
Bristol’s massive 2028 patent cliff could fit well with Astra’s more limited patent exposure.
AbbVie Earnings: Maintaining Our Fair Value Estimate Following a Steady Second Quarter
We’re closely watching data from early-stage pipeline programs that might warrant inclusion in our model.
Ahead of Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
Watching the GLP-1 competitive landscape and pipeline updates as Lilly reports second-quarter earnings.
Novo Nordisk: EU Approval of Wegovy Pill Expands Opportunity, but Cash Pay Raises Systematic Risk
We’re lowering our fair value estimate of Novo stock.
UnitedHealth Earnings: Strength Across the Board Boosts 2026 Outlook
We’ve raised our fair value estimate of UnitedHealth stock.
Johnson & Johnson Earnings: Steady Growth and Good Near-Term Visibility
We’re waiting for data to help size opportunities for some of J&J’s pipeline drugs.
The Best Companies to Own
These companies stand out from the competition and can be good choices for long-term investing.
HCA: Firm Lowers 2026 Guidance on Rising Uninsured Population and Related Pressures
We’ve trimmed our fair value estimate of HCA stock.
As Biopharma Turns to China, ESG Risks and Geopolitics Remain in Focus
Cross-border licensing deals offer pipeline renewal and cost efficiencies but may also introduce risks.
Ionis and AstraZeneca: Shares Tank as Phase 3 ATTR-CM Trial Falls Short of Expectations
We lower our fair value estimate for Ionis Pharmaceuticals.
United States